NCT07185971Recruiting
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss Due to Stroke, Traumatic Brain Injury, or Brain Surgery
PAVE (Parallactic Visual-Field Enhancement) System for Treatment of Chronic Visual Field Loss
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This is a research study to evaluate the effectiveness of the PAVE (Parallactic Visual-Field Enhancement) System for the treatment of chronic visual field loss due to stroke, traumatic brain injury, or brain surgery. The PAVE regimen involves the use of a virtual reality headset to deliver visual stimulation to subjects diagnosed with visual field loss. The primary objective is to demonstrate that there is an improvement in the visual field after use of the PAVE therapy over a period of eight weeks with three sessions per week. The primary outcome is an increase in visual field area as measured with Goldmann-type kinetic perimetry. The secondary outcome will be demonstration that the subjective assessment of visual function using the National Eye Institute Visual Function Questionnaire (NEI-VFQ) is better after PAVE therapy when compared to before therapy. The participants will visit the investigators office at the start of the study to establish a baseline for visual field size and visual field function. The subject will use PAVE in the office or at home three times per week for eight weeks. There will be twenty four therapy sessions in total. At four weeks the subject will visit the office and have perimetry measurements. At eight weeks the subject will visit the office and have perimetry measurements and complete the NEI-VFQ survey. Four weeks after the completion of the therapy sessions a follow up visit will take place where visual field measurement using kinetic perimetry and NEI-VFQ will be administered.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 11 Sept 2025
- Start date
- 16 Mar 2026
- Primary completion date
- Jul 2026
- Lead sponsor
- NeuroAEye LLC
- Diseases
- Stroke
- NCT number
- NCT07185971
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 16 Mar 2026 to the primary completion date, Jul 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of any physical, neurological, or mental disability that would interfere with receiving the therapy.
- Concurrent use of another visual therapy
- Concurrent use of medications judged to affect training (amphetamines, dopamine, etc.)
Other illness
- Presence of ocular or neurological conditions that would interfere with training or cause a visual impairment including no residual vision, disorders of the eye, non-optic nerve heteronymous visual field defects
- Presence of active implantable medical device including but not limited to cardiac pacemakers, defibrillators, nerve stimulators, cochlear implants, etc.
- Subjects with known photosensitive epilepsy.
- Subjects with chronic active infections on the head and face should be excluded from the study
- Patients with known immune disorders for whom an infection could be life threatening should be excluded from the study.
Other
- Insufficient fixation ability
- Use of life supporting external medical device such as infusion pumps, ventricular assist devices, etc.
Who the study is looking for
- This study will include patients at least 6 months after the CVA or TBI or brain surgery event and up to ten (10) years after onset
- The patients shall have a definitive diagnosis of homonymous hemianopia or quadrantanopia or generalized constriction.
Age in the registry: 21 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dr. D. M. Fitzgerald & Associates Coordinator of this site? Confirm its status | Cedar Rapids | United States | Recruiting |
| Neuro-Vision Associates of North Texas Coordinator of this site? Confirm its status | Prospect | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.